Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07649941
PHASE1
A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood
Sponsor: Boehringer Ingelheim
View on ClinicalTrials.gov
Summary
The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.
Official title: The Effect of Multiple Oral Doses of Bosentan on the Single Oral Dose Pharmacokinetics of Zongertinib in Healthy Male Subjects (an Open-label, Two-treatment, Two-period Fixed Sequence Trial)
Key Details
Gender
MALE
Age Range
25 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-06-22
Completion Date
2026-08-19
Last Updated
2026-06-16
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Zongertinib
Zongertinib
DRUG
Bosentan
Bosentan
Locations (1)
Humanpharmakologisches Zentrum Biberach
Biberach, Germany